Updates

Updates and corrections to the 2025 printing of Notes on Injectable Drugs are described on this page. The monographs concerned have already been updated online for subscribers.

For non-subscribers, if there were errors in a previously published monograph, an updated PDF of the relevant monograph is available here for reference or downloading.

There are major changes to the standard format of all monographs coming during 2026 – check back here in April for more news.

In the meantime here are some of the monographs we are currently working on for future updates.

 

New in 2026
Aztreonam + avibactam Benralizumab Bumetanide
Ferric derisomaltose Liothyronine Mepolizumab
Omalizumab Rituximab
Trigger for update: New brand
Dexamethasone Droperidol Furosemide
Trigger for update: Scheduled review
Amoxycillin + clavulanic acid Ceftazidime Ceftriaxone
Ganciclovir Piperacillin + tazobactam Vancomycin
The following monographs have links to the updated PDF:
The following monographs are available to subscribers only:
Amphotericin B (As Liposomal)
  • Updated monograph with new brand
Carboprost
  • Scheduled review – no significant changes
Caspofungin
  • Updated monograph with new brand
Cefazolin
  • Scheduled review – added information on continuous infusions, subcutaneous infusions and OPAT administration
Chloramphenicol
  • Updated monograph with new brands
Clindamycin
  • Updated monograph with new brand
  • Added information on continuous infusions and OPAT administration
Daptomycin
  • Scheduled review – no significant changes
Ocrelizumab
  • Updated monograph with new presentation
  • Added information on subcutaneous administration
The following monographs have links to the updated PDF:
The following monographs are available to subscribers only:
Atracurium Besilate
  • Updated monograph with new brand
Betamethasone Acetate + Betamethasone Sodium Phosphate
  • Scheduled review – no significant changes
Calcium Folinate
  • Updated monograph with new brand
Chlorphenamine
  • Updated monograph with new brand
Deferoxamine
  • Scheduled review – no significant changes
Defibrotide
  • New monograph
Diazoxide
  • Scheduled review – no significant changes
Digoxin-Specific Antibody Fragment F(Ab)
  • Scheduled review – no significant changes
Emicizumab
  • New monograph
Eptifibatide
  • Review prompted by feedback received
Ferric Carboxymaltose
  • Review prompted by feedback received
Folic Acid
  • Scheduled review – no significant changes
Haloperidol Decanoate (Depot)
  • Scheduled review – no significant changes
Icatibant
  • New monograph
Iloprost
  • Scheduled review – no significant changes
Infliximab
  • Review prompted by feedback received
Insulin (Short Acting)
  • Scheduled review – major update on formatting. Separated rapid and short acting insulins
Iron Sucrose
  • Scheduled review – no significant changes
Lorazepam
  • Updated brands in monograph
Methylprednisolone Acetate
  • Scheduled review – no significant changes
Methylprednisolone Sodium Succinate
  • Feedback received
Mycophenolate Mofetil
  • Feedback received
Olanzapine Embonate (Depot)
  • Scheduled review – reconstitution section clarified and table added
Paliperidone (Depot)
  • Updated monograph with new brand
Palivizumab
  • Scheduled review – added multiple administration option in paediatrics
Pantoprazole
  • New monograph
Secukinumab
  • New monograph
Sodium Bicarbonate
  • Scheduled review – updated dilution section
Sodium Nitroprusside
  • Updated monograph with new brand
Teicoplanin
  • Updated monograph with new brand
Tenecteplase
  • Scheduled review – no significant changes
Terbutaline
  • Scheduled review – updated administration section to include continuous infusion and subcutaneous administration
Testosterone
  • Updated monograph with new brand
Vancomycin
  • Feedback received
The following monographs have links to the updated PDF:
The following monographs are available to subscribers only:
Adenosine
  • Updated monograph with new brand
Argipressin (Vasopressin)
  • Scheduled review
  • New title (changed from Vasopressin to bring into line with NZF)
Clonidine
  • Updated monograph with new brand
Digoxin
  • Scheduled review – updated administration section
Eculizumab
  • New monograph
Enoxaparin
  • Scheduled review – updated paediatric administration
Etanercept
  • New monograph
Filgrastim
  • Scheduled review - no significant changes
Flecainide
  • Updated monograph with new brand
Flupentixol (Depot)
  • Scheduled review - no significant changes
Medroxyprogesterone
  • Scheduled review - no significant changes
Mesna
  • Scheduled review – updated administration section
Methylprednisolone Sodium Succinate
  • Scheduled review – updated paediatric administration in response to feedback
Parecoxib
  • Scheduled review – updated paediatric administration
Tetracosactide (Depot)
  • Scheduled review - no significant changes
Tetracosactide (Short Acting)
  • Scheduled review - no significant changes
Zuclopenthixol Decanoate (Depot)
  • Scheduled review - no significant changes
The following monographs have links to the updated PDF:
The following monographs are available to subscribers only:
Acetazolamide
  • Updated monograph with new brand
Ciclosporin
  • Scheduled review - no significant changes
Colistimethate
  • New brand – significant update
Denosumab
  • New monograph
Ferric Carboxymaltose
  • Scheduled review – updated paediatric administration
Flumazenil
  • Scheduled review - no significant changes
Fondaparinux Sodium
  • Scheduled review – additional administration advice
Glucagon Hydrochloride
  • Scheduled review - no significant changes
Lanreotide
  • New monograph
Methylnaltrexone bromide
  • New monograph
Mycophenolate Mofetil
  • Scheduled review - no significant changes
Oxycodone
  • Scheduled review – clarified paediatric administration
Promethazine
  • Scheduled review - no significant changes
Risperidone (Depot)
  • Scheduled review - no significant changes
Tocilizumab
  • Scheduled review – removed unfunded preparations
The following monographs have links to the updated PDF:
The following monographs are available to subscribers only:
Aciclovir
  • Scheduled review - no significant changes
Amoxicillin + Clavulanic Acid
  • Updated monograph with new brand
Azathioprine
  • Scheduled review – no significant changes
Basiliximab
  • Scheduled review – no significant changes
Cefiderocol
  • New monograph
Cefotaxime
  • Scheduled review – updated administration section
Cetuximab
  • New monograph
Diclofenac
  • Scheduled review – no significant changes
Ethanol
  • Scheduled review – no significant changes
Fentanyl
  • Scheduled review – no significant changes
Hydrocortisone
  • Scheduled review – clarified powder displacement value as per manufacturer
Methadone Hydrochloride
  • Scheduled review – no significant changes
Omeprazole
  • Updated monograph with new brands
Paracetamol
  • Scheduled review – no significant changes
Rifampicin
  • Scheduled review – no significant changes
Terlipressin
  • Updated monograph with new brand
Zidovudine
  • Scheduled review – added hazardous warning
Zuclopenthixol Acetate (Acute Use)
  • Scheduled review – no significant changes
The following monographs have links to the updated PDF:
The following monographs are available to subscribers only:
Acetylcysteine
  • Scheduled review - no significant changes
  • Brand updated
Alfentanil
  • Scheduled review - no significant changes
  • Brand updated
Atropine Sulfate
  • Scheduled review - no significant changes
Linezolid
  • Scheduled review - no significant changes
Remdesivir
  • Scheduled review - no significant changes
  • Expanded paediatric dilutions
The following monographs have links to the updated PDF:
The following monographs are available to subscribers only:
Adrenaline
  • Scheduled review – added Epipen and warning box
Alteplase
  • Scheduled review – no significant changes
  • Added latex allergy warning
Amiodarone
  • Scheduled review – general updates to wording and references
Amphotericin B (As Liposomal)
  • Scheduled review – added OPIVA information for community use
Atracurium Besilate
  • Scheduled review – minor updates to all sections
Bivalirudin
  • Scheduled review – brand update and expanded administration and monitoring sections
Calcitonin (Salmon)
  • Scheduled review – minor changes
Calcium Chloride
  • Scheduled review – administration section updated and minor changes to monitoring
Cefoxitin
  • Scheduled review – added available brands, continuous infusion and OPIVA information
Ceftaroline Fosamil
  • Scheduled review – added OPIVA information for community use
Ceftazidime + Avibactam
  • New monograph
Ceftolozane + Tazobactam
  • New monograph
Dantrolene
  • Scheduled review – no significant changes
Doxapram
  • Scheduled review – updated brand and administration
Ephedrine Hydrochloride
  • Scheduled review – major update to administration with removal of IM/SC
  • Brands available updated
Gentamicin
  • Scheduled review – major update to administration with removal of multiple daily dosing indication
  • New brand added
Glucose 50%
  • Scheduled review – minor updates to administration
Glyceryl Trinitrate
  • Scheduled review – major update due to brands
  • Added warning and dilution table
Hyoscine Hydrobromide
  • Scheduled review – no significant changes
Idarucizumab
  • Scheduled review – update to stability out of fridge
Imipenem + Cilastatin
  • Scheduled review – OPIVA information and more compatible fluids added
Iron Polymaltose
  • Scheduled review – no significant changes
Isoprenaline
  • Scheduled review – new brands added and dilution section updated
Ketamine
  • Scheduled review – updated administration and dilution sections
Leuprorelin
  • Scheduled review – minor updates to monograph
Levetiracetam
  • Scheduled review – minor updates to administration and dilution sections
Lidocaine
  • Scheduled review – added new brand and warning box
  • Updated dilution and other information sections
Methylthioninium Chloride (Methylene Blue)
  • Scheduled review – no significant changes
Metronidazole
  • Scheduled review – no significant changes
Milrinone
  • Scheduled review – no significant changes
Moxifloxacin
  • Scheduled review – no significant changes
Naloxone
  • Scheduled review – brand and dilution section updated
Nicardipine
  • New monograph
Noradrenaline
  • Scheduled review – minor updates only
Pamidronate Disodium
  • Scheduled review – updated administration and added dilution table
Phenobarbital
  • Scheduled review – major update to administration with removal of paediatric direct injection due to high rate
  • Updated dilution section
Phenylephrine
  • Scheduled review – no significant changes
Potassium Dihydrogen Phosphate
  • Scheduled review – updates to administration, dilution and monitoring sections
Propofol
  • Scheduled review – updates to administration and dilution section
  • Removed allergy warning as per references
Protamine
  • Scheduled review – updates to administration and monitoring sections
Sodium Bicarbonate
  • Scheduled review – updated administration and dilution sections
Sodium Thiosulfate
  • Scheduled review – available brands updated
Pabrinex (Intravenous)/Syndrex
  • Scheduled review – new brand added
Tacrolimus
  • Scheduled review – no significant changes
Thiamine
  • Scheduled review – available brands updated
Tramadol
  • Scheduled review – updates to administration section, particularly to paedatric administration (new age cut offs)
Tranexamic Acid
  • Scheduled review – updates to administration, dilution and monitoring sections
The following monographs have links to the updated PDF:
The following monographs are available to subscribers only:
Adenosine
  • Scheduled review - no significant changes
Amoxicillin + Clavulanic Acid
  • Brand change
Cefuroxime
  • Brand change
  • Added outpatient antibiotic administration option
Clarithromycin
  • Scheduled review - no significant changes
Dobutamine
  • Scheduled review - no significant changes
Dopamine
  • Scheduled review - no significant changes
Dulaglutide
  • Scheduled review - no significant changes
Epoprostenol
  • New monograph
Famotidine
  • Feedback received – added subcutaneous route
Goserelin
  • Scheduled review - no significant changes
Levocarnitine
  • New monograph
Metaraminol
  • Scheduled review - no significant changes
Natalizumab
  • New monograph
Nimodipine
  • Scheduled review - no significant changes
Ocrelizumab
  • New monograph
Pentamidine
  • New monograph
Phentolamine
  • Scheduled review - no significant changes
Prochlorperazine
  • Scheduled review - no significant changes
Rasburicase
  • Scheduled review - no significant changes
Salbutamol
  • Scheduled review - no significant changes
Sodium Chloride 3% (Hypertonic)
  • Feedback received – peripheral administration added
Sodium Dihydrogen Phosphate
  • Scheduled review - no significant changes
Teriparatide
  • Scheduled review - no significant changes
Thiopental Sodium
  • Scheduled review - no significant changes
The following monographs have links to the updated PDF:
The following monographs are available to subscribers only:
Adalimumab
  • Scheduled review - no significant changes
Aminophylline
  • Review based on feedback received
Desmopressin
  • Scheduled review - no significant changes
Dexmedetomidine
  • Brand change
Dihydroergotamine
  • Scheduled review - no significant changes
Potassium Chloride
  • Review based on feedback received